What supplements are recommended for an adult with pemphigus vulgaris receiving systemic corticosteroids (with or without additional immunosuppressants) to protect bone health and address steroid‑related nutrient deficiencies?

Calcium and Vitamin D Supplementation for Pemphigus Vulgaris Patients on Corticosteroids

All adults with pemphigus vulgaris receiving prednisone >7.5 mg daily for more than 3 months should be prescribed calcium and vitamin D supplementation, with bisphosphonate therapy added based on fracture risk assessment. 1, 2

Immediate Supplementation Requirements

For patients starting or continuing systemic corticosteroids:

• Calcium and vitamin D supplementation should begin as soon as possible after initiating ≥2.5 mg/day prednisone treatment expected to last >3 months 1
• This recommendation has the strongest evidence (Level IA) and near-unanimous expert agreement (95% strength of recommendation) 2
• The supplementation is essential because calcium and vitamin D have been proven to reduce glucocorticoid-induced bone loss and fractures 2

Critical Context for Pemphigus Vulgaris

Pemphigus vulgaris patients face particularly high risk because:

• 76% of pemphigus vulgaris patients have a history of systemic corticosteroid use 3
• These patients show significantly elevated rates of osteopenia (adjusted OR 10.07) and osteoporosis (adjusted OR 4.19) compared to controls 3
• There is a significant statistical interaction between pemphigus vulgaris and corticosteroid use as predictors of osteoporosis, meaning the combined effect is worse than either factor alone 3

Fracture Risk Assessment Algorithm

Within 6 months of starting corticosteroids, perform:

For patients ≥40 years old:

• FRAX score calculation (with GC correction if prednisone >7.5 mg daily)
• BMD measurement via DXA
• Vertebral fracture assessment (VFA) or spinal x-rays 1

For patients <40 years old:

• BMD with VFA or spinal x-rays (FRAX not validated in this age group) 1

Bisphosphonate Decision Framework

Calcium and vitamin D alone do not totally prevent glucocorticoid-induced bone loss 2. Bisphosphonates are superior and should be added based on:

Strong indication (oral bisphosphonates strongly recommended):

• High or very high fracture risk adults 1

Conditional indication (bisphosphonates conditionally recommended):

• Moderate fracture risk adults 1
• Risk factors include: decreased BMD, female gender, older age, postmenopausal status, low body mass index 2

Key caveat:

At the same BMD level, postmenopausal patients on glucocorticoids are more prone to fractures than those without glucocorticoid therapy 2

Additional Protective Measures

Beyond bone health supplementation, all patients should receive:

• Weight-bearing exercise recommendations
• Smoking cessation counseling
• Alcohol intake limitation (avoid excessive use)
• Age-appropriate dietary calcium and vitamin D intake guidance 1

Monitoring Requirements

During treatment, monitor based on glucocorticoid dose and duration:

• Body weight
• Blood pressure
• Serum lipids (pemphigus patients have increased hyperlipidemia risk) 3
• Blood glucose (adjusted OR 5.68 for type 2 diabetes in pemphigus patients on steroids) 3

Gastric Protection

If the patient is taking concomitant NSAIDs with corticosteroids, prescribe proton pump inhibitors or misoprostol (or switch to a COX-2 selective inhibitor) 2. This has Level I evidence with 91% strength of recommendation.

Common Pitfall

The most critical error is delaying supplementation until bone loss is detected. Supplementation must begin prophylactically when corticosteroids are initiated, not after complications develop, as prevention is far more effective than treatment of established osteoporosis 1, 2.